A prospective, multicenter, single-arm clinical trial of PD-1 inhibitors in combination with radiotherapy and GM-CSF, sequentially followed by IL-2 (PRaG 2.0) therapy in advanced refractory solid tumors.

Who was studied?

34 enrolled patients; 28 completed at least one tumor assessment.

What does the publication report?

ORR was 21.4% and DCR 71.4%. Median PFS and OS had not been reached at the reported cutoff.

Safety findings

Grade ≥3 treatment-related events occurred in 3 patients (8.8%).

How should we interpret it?

Conference-level, non-randomized evidence. Linked reports may include the same participants and should not be counted as independent trials.

Read the original source

This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.

A prospective, multicenter, single-arm clinical trial of PD-1 inhibitors in combination with radiotherapy and GM-CSF, sequentially followed by IL-2 (PRaG 2.0) therapy in advanced refractory solid tumors. · DOI: 10.1200/JCO.2022.40.16_suppl.2609

• Official publication source ↗
• Publisher via DOI ↗

Related publications from the same research program

• PD-1 inhibitors combined with radiotherapy and GM-CSF, sequentially followed by IL-2 regimen in advanced refractory solid tumors: a prospective, multicenter clinical trial.
• PRaG 2.0: the 2023 ASTRO conference report
• PRaG 2.0: the 2023 ASCO interim report

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.